Overview

3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Status:
Not yet recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Phase 2 open label trial to investigate the safety and potentially efficacy of 3K3A-APC in patients with Amyotrophic Lateral Sclerosis (ALS).
Phase:
Phase 2
Details
Lead Sponsor:
Macquarie University, Australia
Collaborator:
ZZ Biotech, LLC